热门资讯> 正文

Aileron Therapeutics报告第二季度业绩

2026-08-14 18:54

Aileron Therapeutics(ALRN) 0
XMax Inc(XMAX) 0

Aileron Therapeutics press release (RNTX): Q2 Net loss was $6.4 million for the quarter ended June 30, 2026, compared to $6.8 million for the comparable prior year period
Cash position: Cash, cash equivalents and marketable securities were $43.6 million as of June 30, 2026. The Company’s cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund its operations into the first quarter of 2028.

More on Aileron Therapeutics

Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha’s Quant Rating on Aileron Therapeutics
Historical earnings data for Aileron Therapeutics
Financial information for Aileron Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。